Newron Pharmaceuticals S.p.A.

BATS-CHIXE:NWRNZ Stock Report

Market Cap: CHF 314.2m

Newron Pharmaceuticals Valuation

Is NWRNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NWRNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 140.36
Fair Value
88.8% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: NWRNZ (CHF15.76) is trading below our estimate of fair value (CHF140.36)

Significantly Below Fair Value: NWRNZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NWRNZ?

Key metric: As NWRNZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NWRNZ. This is calculated by dividing NWRNZ's market cap by their current earnings.
What is NWRNZ's PE Ratio?
PE Ratio13.4x
Earnings€25.33m
Market Cap€338.40m

Price to Earnings Ratio vs Peers

How does NWRNZ's PE Ratio compare to its peers?

The above table shows the PE ratio for NWRNZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.3x
ANCR Animalcare Group
57.6xn/aUK£171.8m
EAH ECO Animal Health Group
38.2x22.21%UK£62.7m
HCM HUTCHMED (China)
5.2x-64.67%UK£1.9b
HIK Hikma Pharmaceuticals
12.2x13.24%UK£3.5b
NWRNZ Newron Pharmaceuticals
13.4x45.19%CHF 314.2m

Price-To-Earnings vs Peers: NWRNZ is good value based on its Price-To-Earnings Ratio (13.4x) compared to the peer average (28.1x).

Price to Earnings Ratio vs Industry

How does NWRNZ's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies10PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NWRNZ is good value based on its Price-To-Earnings Ratio (13.4x) compared to the European Pharmaceuticals industry average (24.4x).

Price to Earnings Ratio vs Fair Ratio

What is NWRNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NWRNZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NWRNZ's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NWRNZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 15.82
CHF 18.09
+14.33%
26.80%CHF 23.02CHF 11.50n/a3
Nov ’26CHF 14.42
CHF 18.09
+25.43%
26.80%CHF 23.02CHF 11.50n/a3
Oct ’26n/a
CHF 18.05
0%
26.74%CHF 22.96CHF 11.49n/a3
Sep ’26n/a
CHF 18.20
0%
27.09%CHF 23.20CHF 11.49n/a3
Aug ’26n/a
CHF 18.04
0%
27.67%CHF 23.14CHF 11.26n/a3
Jul ’26n/a
CHF 17.86
0%
27.65%CHF 23.23CHF 11.31n/a3
Jun ’26n/a
CHF 17.86
0%
27.65%CHF 23.23CHF 11.31n/a3
May ’26n/a
CHF 17.63
0%
27.77%CHF 22.97CHF 11.14n/a3
Apr ’26n/a
CHF 15.81
0%
19.69%CHF 18.75CHF 11.50n/a3
Mar ’26n/a
CHF 15.64
0%
19.11%CHF 18.49CHF 11.51n/a3
Feb ’26n/a
CHF 15.64
0%
19.11%CHF 18.49CHF 11.51n/a3
Jan ’26n/a
CHF 14.39
0%
12.44%CHF 16.86CHF 12.70n/a3
Dec ’25n/a
CHF 14.42
0%
12.56%CHF 16.94CHF 12.76n/a3
Nov ’25n/a
CHF 14.42
0%
12.56%CHF 16.94CHF 12.76CHF 14.423
Oct ’25n/a
CHF 14.42
0%
12.56%CHF 16.94CHF 12.76n/a3
Sep ’25n/a
CHF 14.30
0%
15.23%CHF 17.31CHF 12.23n/a3
Aug ’25n/a
CHF 14.30
0%
15.23%CHF 17.31CHF 12.23n/a3
Jul ’25n/a
CHF 14.30
0%
15.23%CHF 17.31CHF 12.23n/a3
Jun ’25n/a
CHF 14.45
0%
14.27%CHF 17.29CHF 12.46n/a3
May ’25n/a
CHF 14.54
0%
14.01%CHF 17.32CHF 12.48n/a3
Apr ’25n/a
CHF 12.99
0%
4.51%CHF 13.81CHF 12.45n/a3
Mar ’25n/a
CHF 11.34
0%
22.67%CHF 13.60CHF 7.74n/a3
Feb ’25n/a
CHF 9.15
0%
26.66%CHF 12.59CHF 7.18n/a3
Jan ’25n/a
CHF 7.39
0%
3.50%CHF 7.65CHF 7.13n/a2
Dec ’24n/a
CHF 7.39
0%
3.50%CHF 7.65CHF 7.13n/a2
Nov ’24n/a
CHF 7.39
0%
3.50%CHF 7.65CHF 7.13n/a2
CHF 18.11
Fair Value
13.0% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/19 20:56
End of Day Share Price 2025/11/19 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas MeyerBaader Helvea Equity Research
Jyoti PrakashEdison Investment Research
Lucy CodringtonJefferies LLC